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Aims.— To compare the impact of three patient counselling strategies for lifestyle changes and
to assess the safety and efﬁcacy of ezetimibe on top of statin therapy in hypercholesterolemic
high risk patients.
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du LDL-C est légèrement supérieure à celle habituellement rapportée à court terme avec cette
dose d’ezetimibe. Diminuer la consommation de graisses semble plus facile qu’augmenter
l’activité physique. Cette étude conﬁrme la bonne efﬁcacité et la tolérance à court terme
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bbreviations
ALT alanine aminotransferase
AST aspartate aminotransferase
CK creatine kinase
GEE generalized estimating equations
HDL-C high-density lipoprotein cholesterol
MG-CoA hydroxy-methyl-glutaryl-coenzyme A reductase
LDL-C low-density lipoprotein cholesterol
REML restricted maximum likelihood
TG triglycerides
TWICE ezetimibe together with any statin cholesterol
enhancement
ULN upper limit of normal
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ackground
iet and physical activity are the key to the treatment
f dyslipidemia and prevention of cardiovascular disease,
hether used alone or in combination with drug therapy
1,2]. Therapeutic lifestyle changes confer large and usu-
lly more than additive beneﬁts in terms of risk reduction
2,3].
Much has been learned during the past two decadesP.G. Steg et al.
Methods.— Open, cluster randomized 3-parallel group trial. Physicians were randomized
between patient motivation on: diet or physical exercise or both. Counselling was adapted
to the patient’s baseline Prochaska stage of change. High cardiovascular risk patients,
with LDL-C above or equal to 3mmol/L despite statin therapy for at least 3months,
were enrolled. Ezetimibe (10mg/day) and patient counselling were started at the same
time. Target goal was deﬁned as total cholesterol less than 5mmol/L and LDL-C above 3
mmol/L.
Results.— Overall 428 physicians enrolled 1496 patients. At baseline, LDL-C was
3.9± 0.9mmol/L and total cholesterol was 6.1± 1.1mmol/L. LDL-C decreased by
−30.4± 19.3% and 869 (62%) patients achieved target goal. No difference was shown
between randomisation groups. However, improvements in diet consumption patterns were
more easily obtained than improvement in physical activity stage of change in non-active
patient at baseline.
Conclusions.— The marked short-term impact (−30%) on LDL-C, although similar between
the three groups, slightly exceeds usual LDL-C reductions achieved by this dose of eze-
timibe. Decreasing fat consumption seems easier than increasing physical activity. This
study conﬁrms the good efﬁcacy, short-term tolerability and safety of ezetimibe on top of
statins.
© 2008 Elsevier Masson SAS. All rights reserved.
Résumé
Objectif.— Comparer trois stratégies de conseils de modiﬁcation du mode de vie et évaluer
la tolérance et l’efﬁcacité d’ezetimibe ajouté au traitement par statine chez des patients
hypercholestérolémiques à haut risque.
Méthodes.— Essai randomisé par grappes, en trois groupes parallèles, en ouvert. Les médecins
étaient randomisés entre : motiver le patient sur le régime, motiver sur l’activité physique
ou motiver sur les deux. Les conseils étaient adaptés au stade de motivation (stade de
Prochaska) du patient. Les patients sélectionnés étaient à haut risque cardiovasculaire,
avec un LDL-C supérieur ou égale à 3mmol/L malgré un traitement par statine supérieur
ou égal à trois mois. Ezetimibe (10mg/j) et conseils au patient étaient débutés simul-
tanément. L’objectif était cholestérol total inférieur à 5mmol/L et LDL-C inférieur à
3mmol/L.
Résultats.— Au total 428 médecins ont sélectionnés 1496 patients (LDL-C : 3,9± 0,9mmol/L,
cholestérol total : 6,1± 1,1mmol/L). Le LDL-C a diminué de −30,4± 19,3 % et 869 (62 %)
patients ont atteint l’objectif thérapeutique. Il n’a pas été mis en évidence de différence entre
les groupes de randomisation. Il a été plus facile d’améliorer la motivation sur les habitudes
alimentaires que sur l’activité physique des patients non encore passés à l’action à l’inclusion.
Conclusions.— Bien que comparable entre les trois groupes, la diminution importante (−30%)bout successful modiﬁcation of diet and lifestyle param-
ters, using behavioural science [4—7]. For example, the
rochaska and DiClementi [8] ‘‘stages of change’’ model
ostulates that both cessation of high-risk behaviours and
he acquisition of healthy behaviours involve progres-
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sion through ﬁve stages of change: pre-contemplation,
contemplation, preparation, action and maintenance [9].
This transtheoretical model has been shown to general-
ize across a broad range of problem behaviours (including
diet, exercise and weight control) [10—12]. The stage of
change was conceived to help or guide planned change
efforts. This study was designed to estimate the feasibil-
ity of the estimation of stage of change in ambulatory
hypercholesterolemic patients and to compare three moti-
vation strategies adapted to the patient baseline stage of
change.
Adding ezetimibe to ongoing statin therapy leads to
substantial additional reduction in LDL cholesterol levels
[13]. Ezetimibe was found to be safe and well tolerated
in clinical trials. Post marketing studies allow a bet-
ter assessment of drug safety in clinical practice. This
post-marketing trial therefore provided an opportunity
to conﬁrm the safety and efﬁcacy of ezetimibe treat-
ment in co-administration with a statin in routine clinical
practice.
Methods
Patients
Patients with primary hypercholesterolemia and low-
density lipoprotein (LDL-C) greater or equal to 3mmol/L
(115mg/dL) currently treated with a statin for at least
3months and between the ages of 18 and 80 were enrolled.
Patients were at high cardiovascular risk: secondary preven-
tion (established cardiovascular organ damage or disease)
or in primary prevention with one or more cardiovascular
risk factors (diabetes mellitus, sustained arterial hyperten-
sion, current smoker, man aged 45 or older, menopause
or woman aged 55 or older, family history of prema-
ture sudden death or myocardial infarction) other than
hypercholesterolemia [2]. A family history of premature
event was deﬁned as a sudden death or myocardial infarc-
tion in a ﬁrst degree male relative man before 55 or
ﬁrst degree female relative before 65 [2]. Before start-
ing intervention, it was checked that TG level was below
4.52mmol/L (400mg/dL), liver transaminases (ALT, AST)
less or equal to 2-fold the ULN, CK less or equal to 2-fold
ULN and creatinin clearance (Cockroft formula) higher than
30ml/min.
Key exclusion criteria included:
• use of other lipid-lowering agents within the last
3months including HMG-CoA reductase inhibitors other
than the current statin, ﬁsh oils, cholestyramin, niacin
(> 200mg/day) and ﬁbrates;
• any modiﬁcation in the statin treatment within the last
6weeks;
• any contra-indication to statin or ezetimibe treatment;
• myocardial infarction, unstable angina, coronary artery
bypass surgery, or angioplasty (coronary or peripheral
artery) within the last 3months;
• any immunosuppressant including cyclosporine;
• uncontrolled hypothyroidism;
• active liver disease including known infection by HBs or
HBc virus or known HIV infection.
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tudy design
his is an open, cluster-randomised, 3-parallel group trial
omparing three counselling strategies on lifestyle changes.
Cluster randomisation was used, i.e. the physician was
hosen as the unit of randomisation, in an attempt to limit
reatment contamination. Physicians were randomised in
1:1:1 ratio before systematic screening and recruitment
etween [14,15]:
motivation on diet (Group 1);
motivation on physical activity (Group 2);
both (Group 3).
The trial was approved by the ethic committee and
ll subjects gave written informed consent before par-
icipating. The ClinicalTrials.gov identiﬁer of the trial is
CT00328523.
ntervention
valuation of patient stage of change
n all patients, Prochaska stage of change and physical activ-
ty were estimated before the start of intervention and at
he end of intervention, using a self-administered question-
aire. French translation of validated questionnaires were
sed. The ﬁve stages of change were deﬁned for dietary fat
eduction and for a Mediterranean nutrition pattern, with
espect to two aspects of a Mediterranean diet: consump-
ion of ﬁsh and vegetables. These stages of change reﬂect
articipants’ readiness to reduce their dietary fat intake
nd to adopt a Mediterranean diet [6,7]. The ﬁve stages of
hange were deﬁned for physical exercise using four ques-
ions [11,12].
atient counselling
atients received a leaﬂet corresponding to their Prochaska
tage of change. The leaﬂet summarizes counselling given
o the patient according to the randomisation group
f the physician (counselling based on diet, physical
ctivity or both). The patient leaﬂets for the various
ypes of Prochaska stage and type of counselling (diet,
r physical activity or both) are available online at
ww.cncardio.org/news00010d08.asp.
Counselling was based on the Second Joint Task Force of
uropean and other Societies on Coronary Prevention [16].
Mediterranean diet was recommended in this trial as well
s the recommendation to reduce fat intake, in order to
ave a low cholesterol diet. Patients were instructed to eat
wo or more servings of fruit per day, vegetables once per
ay at least and to replace red meat by ﬁsh twice per week
7,17,18]. Patients were also instructed to reduce butter,
ream and cheese consumption [2]. As far as physical activ-
ty was concerned, patients were professionally encouraged
nd supported to increase their physical activity safely to
level associated with the lowest risk of cardiovascular
isease. Aerobic exercise (e.g. walking, swimming or bicy-
ling) for 20min. three times a week was recommended.
hysicians emphasized the importance of physical activity
n giving the patient a sense of well-being. For the elderly
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r poorly conditioned or, people in the pre-contemplation,
ontemplation or preparation stages of change, any amount
f physical activity was recommended such as strolling or
ardening with emphasis on the possible beneﬁt.
Physicians were not prevented from giving any other oral
ounselling on lifestyle changes that they thought might be
seful for the patient.
zetimibe therapy
zetimibe therapy was not part of randomisation and all
atients received ezetimibe in addition to the statin they
lready received. The statin dose was kept unchanged.
low of the study
ig. 1 summarizes the study design. At the end of a run-in
eriod of 1—2weeks and after counseling have been given,
ll patients were instructed to take ezetimibe 10mg once
aily in the evening on top of the dose of statin they already
eceived.
Lipid and safety parameters were assessed after 6 to
0weeks of ezetimibe treatment, in a core laboratory [19].
t the third and last visit in the trial, performed one week
fter blood sampling, all patients were asked to complete
he same self-administered questionnaire in order to esti-
ate physical activity and the stages of change for physical
xercise, dietary fat reduction and Mediterranean diet.
nformation on events and compliance with drug treatment
ere also recorded.
tatistical analysis
he primary efﬁcacy criterion was the percentage
f patients with total plasma cholesterol (TC) less
han 5mmol/L (190mg/dL) and LDL-C above 3mmol/L
115mg/dL) at the end of the trial, 6 to 10weeks after
he start of intervention [1]. The secondary efﬁcacy criteria
ere:
the percentage changes in LDL-C, HDL-C and TG from ran-
domization to endpoint after 6—10weeks of ezetimibe
treatment;
the percentage of patients with LDL-C less than
2.58mmol/L (100mg/dL) at the end of the trial;
the percentage of patients with estimation of stage of
change;
the percentage of patients in a pre-action stage of change
(precontemplation or contemplation or preparation stage
of change) at baseline having moved to an action stage of
change at end of trial.
Safety and tolerability of treatment were secondary cri-
eria.
It was estimated that at most 70% of the patients would
chieve target lipid level and that each physician would
nclude three patients [20]. In a conventional randomised
rial, without cluster design, 996 patients in every treat-
ent group enabled detection of a difference between two
reatment groups of 6% at least, with 80% power, at the
% signiﬁcance level [21]. For a cluster-randomised trial,
sing an intracluster correlation factor of 0.019, the stan-
ard sample estimates had to be inﬂated by a factor of 1.038
c
(
(
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14,22,23]. Therefore, a total of 3102 patients had to be
nrolled by 1034 physicians.
The unit of analysis is the patient [14]. Categorical
arameters were compared between the three therapeutic
trategies using a chi-square adjusted for intracluster cor-
elation, followed by logistic GEE using a model including
erms for treatment, baseline LDL-C, age, gender, base-
ine stage of change and statistically signiﬁcant interaction
erms [14,24]. Percentage change data were expressed as
ean or median percentage change (95% CI). Percentage
hange of LDL-C and other lipid parameters were com-
ared between the three therapeutic strategies using a
ixed model REML, with intervention arm and covariates
s ﬁxed effects and cluster as random effect [25,26].
djustment was done on baseline LDL-C, age, gender, and
aseline stage of change. Interaction terms were tested.
ntracluster correlation coefﬁcients were estimated from
he data. Percentage of patients in a pre-action stage
t baseline having improved their stage of change by
t least one level at the end of the trial was com-
ared between randomisation groups. However, in order
o avoid problems related to multiplicity only evolution
f Prochaska stages of change for fat consumption and
hysical activity were statistically compared and descrip-
ive statistics were used for other Prochaska stages of
hange: ﬁsh and vegetable consumptions. Statistical anal-
sis was based on Intent to Treat, including all patients
aving received one dose of ezetimibe at least and
ith one determination of LDL-C before and after start
f ezetimibe. All patients having received one dose of
zetimibe at least were included in the safety analy-
is.
Statistical analysis was conducted using SAS® software
ersion 8.2 (SAS Institute, Inc., Cary, NC).
esults
ut of 1059 randomised physicians (978 cardiologists and 81
eneral practitioners [GP]) 506 physicians (438 cardiologists
nd 68GP) selected 2232 patients between June 2004 and
ecember 2005. Enrollment, being much lower than antic-
pated, was stopped after 2232 patients were enrolled
y 428 physicians. Of the 2232 patients, 1496 (67%) had
eceived at least one dose of ezetimibe; 1411 (94%) patients
ere included in the efﬁcacy analysis: 493 patients in Group
, 490 patients in Group 2 and 428 patients in Group 3.
atient characteristics
aseline demographics, medical history and lipid levels
ere similar between treatment groups (Table 1). Approx-
mately one-third of the patients had a known history of
yocardial infarction, and approximately half were treated
or hypertension. At baseline, LDL-C was 3.9± 0.9mmol/L
151± 35mg/dL) and total cholesterol was 6.1± 1.1mmol/L
234± 39mg/dL).Among statins used at baseline, pravastatin was the most
ommonly used (n = 475 [34%]), followed by atorvastatin
n = 401 [29%]), rosuvastatin (n = 188 [13%]), simvastatin
n = 185 [13%]), and ﬂuvastatin (n = 153 [11%]). The median
aily statin dose was 10mg for rosuvastatin, 20mg for
Results of TWICE trial 727
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rFigure 1. Design of TWICE. Physicians were randomised and train
atorvastatin, pravastatin and simvastatin and 80mg for ﬂu-
vastatin.
In general, the three motivation groups were well bal-
anced regarding Prochaska stages of change. At baseline,
compliance with dietary guidelines was more frequent than
compliance with physical activity guidelines: nearly 60%
of the patient reported restriction in fat diet for more
than 6months when only approximately 45% of the patient
reported exercising three times or more per week during at
least 20min. for more than 6months.
After the initial blood sampling and before the start of
intervention, irrespective of the motivation randomisation
I
a
A
sefore starting patients selection.
roup, most of the patients were motivated on diet and
hysical exercise. In fact, more than three quarters of the
hysicians gave oral counselling on lifestyle change not given
y randomisation group in addition to the leaﬂet of their
andomisation group (Table 2).mprovement in stage of change in patients in
pre-action stage at baseline
t the end of the trial, most of the patients in a pre-action
tage of change at baseline had improved their Prochaska
728 P.G. Steg et al.
Table 1 Baseline characteristics of patients by motivation randomisation groups.
Diet n = 493 Physical activity n = 490 Both n = 428
Age (years) 60.4 (10.6) 60.5 (11.1) 61.0 (10.7)
Male 325 (66) 330 (67) 267 (62)
BMI (kg/m2) 27.2 (4.2) 27.2 (4.3) 27.1 (4.0)
Obesity 105 (21) 115 (23) 91 (21)
Current smoker 72 (15) 61 (12) 58 (14)
Treated hypertension 258 (52) 228 (47) 227 (53)
Diabetes mellitus 57 (12) 57 (12) 38 (9)
Microalbuminuria 11 (2) 11 (2) 11 (3)
History of coronary artery disease 220 (45) 233 (48) 194 (45)
History of myocardial infarction 111 (34) 106 (31) 71 (24)
Lower limb arteriopathy 48 (15) 41 (12) 45 (15)
Total-C (mmol/L) 6.1 (1.1) 6.0 (1.1) 6.0 (0.9)
LDL-C (mmol/L) 3.9 (0.9) 3.9 (1.0) 3.9 (0.8)
HDL-C (mmol/L) 1.4 (0.4) 1.4 (0.4) 1.4 (0.4)
TG (mmol/L) 1.7 (0.9) 1.6 (0.9) 1.6 (0.8)
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tage of change by at least one level whatever the lifestyle
arameter (Fig. 2). Among the 593 patients who were in a
re-action stage of change for physical activity at baseline,
00 (50.6%) patients had improved their stage of change by
t least one stage by the end of the trial and most of them
ad started to exercise at least three times per week for
0min. This proportion was evenly distributed across physi-
ian randomization groups (p = 0.21).
On the other hand, 142/216 (65.7%) patients with no
estriction in fat diet at baseline had improved their stage
f change by at least one stage at end of trial (Fig. 2).
atients of Group 2 in a pre-action stage of change for fat
onsumption at baseline were less likely to have started
ecreasing fat consumption at end of trial than in the
wo other randomisation groups (Fig. 2, p < 0.001 between
roups).
ipid data at end of trial
he mean duration of ezetimibe treatment was 72± 16
ays. Overall, 869 (62%) patients achieved target lipid goals
deﬁned as LDL less than 3mmol/L [115mg/dL] and total
holesterol less than 5mmol/L [190mg/dL]) (95% conﬁ-
ence interval [59%—64%]). No signiﬁcant difference was
hown between groups (p = 0.34 with no adjustment except
n cluster, p = 0.50 after adjustment on all covariates)
t
o
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Table 2 Motivation of the patient by the physician by physici
Counselling given by the physician Randomisation
Diet n = 493
Counselling on diet 481 (98%)
Counselling on physical activity 359 (73%)a
a Oral counselling on lifestyle change not given by randomisation.Fig. 3). In 725 (51%) patients, LDL-C was below 2.58mmol/L
100mg/dL) at the end of trial.
The mean effect on LDL-C lowering efﬁcacy was
0.4± 19.3% overall and was similar across randomization
roups (p = 0.82 with no adjustment except on cluster,
= 0.59 between groups after adjustment on all covari-
tes) (Fig. 4). No signiﬁcant difference was found between
andomisation groups for any of the lipid parameters
Fig. 4). Mean HDL-C did not change and TG slightly
ecreased (−7.5± 35.6%) in all motivation randomisation
roups (p = 0.66 between groups with no adjustment except
n cluster, p = 0.62 after adjustment on all covariates).
afety and tolerability of ezetimibe
levations in CK≥ 5×ULN were observed in one patient at
aseline and in two (0.1%) patients after start of ezetim-
be. Transaminases≥ 3×ULN were observed in four (0.3%)
atients at baseline and in one (0.1%) patient on statin
nd ezetimibe. No rhabdomyolysis (deﬁned as reported by
he investigator or CK≥ 5×ULN with clinical symptoms
r CK≥ 10×ULN with or without clinical symptoms) was
eported. Myalgia or cramps were recorded in 38 (3%)
atients on statin and ezetimibe. Treatment was stopped
ecause of side effects in 50 (3%) patients.
an randomisation groups.
group of the physician
Physical activity n = 490 Both n = 428
383 (78%)a 402 (94%)
476 (97%) 403 (94%)
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Figure 2. Percentage of patients in a pre-action stage of change at baseline with at least one improvement in stage of change. Pre-action
ge o
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Within the TWICE study, ezetimibe and lifestyle changes
were very effective in achieving LDL targets in high-is deﬁned by a precontemplation, contemplation or preparation sta
are displayed. Preaction = precontemplation, contemplation or pre
only for Physical activity and Decrease in fat consumption.
Discussion
This trial is the ﬁrst to compare patient counselling strate-
gies in patients at risk of cardiovascular disease using the
Prochaska transtheorical model.
It seems easier to make a patient decrease his/her fat
consumption than to start or increase physical exercise.
In TWICE, compliance with diet guidelines was more often
reported at baseline than compliance with physical exercise
recommendations and with intervention, stage of change for
fat consumption was more likely to improve than stage of
Figure 3. Percentage of patients at cholesterol target goals after
treatment by motivation randomisation groups.
r
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t
ef change. Only patients in a preaction stage of change at baseline
ion stage of change. Statistical comparison between groups done
hange of physical exercise in pre-action patients. This is as
dds with a previous study performed in the United States
hich reported that physical activity was more improved
han fat consumption [27]. Country habits might explain this
iscrepancy.isk patients with persistently elevated cholesterol levels
espite statin monotherapy. LDL-C through the use of statins
as been shown to be an extremely effective method for
igure 4. Mean percentage change in lipid parameters by motiva-
ion randomisation groups. Mean percentage change with standard
rror (adjustment on cluster only).
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owering cardiovascular risk [28]. Within the TWICE study, if
he administered statin dose was often lower than the stan-
ard statin dose, the 30% LDL-C reduction observed in the
resent study is more important than what might have been
xpected after doubling the statin dose and slightly more
han the 25—26% expected after addition of ezetimibe in
he context of clinical trials [13,29—31]. In another study in
56 patients, treated by statin for at least four weeks, addi-
ion of ezetimibe led to a more than 35% LDL-C reduction,
owever, statin doses were lower than in the present trial
32].
Although the interpretation is limited by intergroup
rossover by physicians, a smaller than anticipated trial
ize and by the absence of a true control group managed
onventionnally without structured counselling, the almost
dentical lipid changes observed in the three groups sug-
est that all motivation strategies have similar and possibly
imited short term efﬁcacy on lipids. This is consistent
ith other published studies [33—35]. In TWICE, counselling
as given only once and it cannot be ruled out that rep-
tition of counselling over a longer duration would have
mpacted more lipid outcomes. Furthermore, long-term
hanges in lifestyle, including physical exercise and diets
igh in fruits, vegetables, whole grains, and unsaturated
atty acids are expected to decrease cardiovascular risk per
e independently of their effect on conventional risk factors
2].
According to the European guidelines on cardiovascular
revention, moving forward in small consecutive steps is one
ey to successful long-term change in behaviour [36]. How-
ver, results of the present study suggest that counselling
n diet and physical activity can be given simultaneously
s recommended by the French recommendations on treat-
ent of dyslipidemia updated in 2005 [37]. It is noteworthy
hat TWICE was started before the release of those recom-
endations and was based on the European and American
uidelines [1,2,16].
We cannot rule out that compliance to lipid-lowering
edications also increased with intervention. It is esti-
ated that 60% of individuals prescribed lipid-lowering
edications are non adherent and motivation based on
he Prochaska transtheorical model improves adherence
27,38].
In this high-risk population, controlling cholesterol levels
s of particular importance and the dramatic LDL-C reduction
llows 62% of patients not controlled by statin monother-
py to reach the therapeutic goal. In addition, 51% of the
atients had a LDL-C below 2.58mmol/L (100mg/dL) at trial
nd, a level which has been suggested to be an appropriate
arget for most of the patients at high-cardiovascular risk,
ccording to the updated American and European guidelines;
he last ones being made available after the start of TWICE
36,39].
Despite a greater reduction in LDL-C, the percentage of
atients at goal in the TWICE study is slightly lower than
n an American community-based, double-blind randomized
rial of ezetimibe added to statin therapy [13]. However,
aseline LDL-C levels (3.2mmol/L) were lower than in the
resent study.
The present study conﬁrms the good efﬁcacy on lipid
evels and short-term tolerability of ezetimibe added to
ifestyle changes and statins.
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onclusions
n conclusion, in the three groups, more than 60% patients
et target LDL-C levels. The marked impact (−30%) on
DL-C, although similar between the three groups, slightly
xceeds usual LDL-C reductions achieved by this dose of
zetimibe. Decreasing fat consumption seems easier than
ncreasing physical activity. TWICE study conﬁrms the good
fﬁcacy on lipid levels and short-term tolerability ezetimibe
n top of statins.
unding
unding and sponsorship for the TWICE trial were provided
y Laboratoires Merck Sharp & Dohme-Chibret, Paris France,
n behalf of MSP Singapore Company, LLC.
ist of the Investigators who enrolled at
east one patient
ARRAS Reda 06240 BEAUSOLEIL (Cardiologue), ABOU BADRA
ernard 31076 TOULOUSE Cedex 3 (Cardiologue), ADEG-
ON Kedi 09200 St GIRONS (Cardiologue), AGBESSI KOSSI
pollinaire 59000 LILLE (Cardiologue), AIMOUCH Naceur
7000 EVREUX (Cardiologue), AKESBI Abdel 95602 EAUBONNE
Cardiologue), ALBESSARD Franck 14000 CAEN (Cardio-
ogue), ALLAOUCHICHE Thierry 13300 Salon de Provence
Cardiologue), ALMAZOR Michel 44600 St NAZAIRE (Car-
iologue), AMEUR HEDRICH Christiane 68100 MULHOUSE
Cardiologue), AMLAIKY Ahmed 68200 MULHOUSE (Car-
iologue), AMMOR Mohammed 81000 ALBI (Cardiologue),
MORETTI Richard 95000 CERGY (Cardiologue), ANAYE Bas-
am 59120 LOOS (Cardiologue), ANDRIEU Marc 12000 RODEZ
Cardiologue), ANGUENOT Thierry 25000 BESANCON (Car-
iologue), ANTELIN Charles-Harry 17000 LA ROCHELLE
Cardiologue), ARNOU Robert 49000 ANGERS (MG), ASSULIN
eddy 95310 St Ouen L’Aumone (Cardiologue), ASSUNCAO
rmindo 59220 DENAIN (MG), ATTALI Pierre 67000 STRAS-
OURG (Cardiologue), AUBERGE Jean-Maurice 13270 fos
ur mer (Cardiologue), AUBERT Jean-Marc 06370 Mouans
artoux (Cardiologue), AUBERT Pierre 83110 SANARY Sur
ER (Cardiologue), AUBRY Jacques 13150 TARASCON (Car-
iologue), AUDOUIN Philippe 75007 PARIS (Cardiologue),
UPIAIS Frédérique 44240 LA CHAPELLE SUR ERDRE (MG),
URE Pascal 49000 ANGERS (MG), AVINEE Pierre 80094
MIENS Cedex 3 (Cardiologue), AYRIVIE Pierre-Antoine 34500
EZIERS (Cardiologue), BAHSOUN Roda 31077 TOULOUSE
edex (Cardiologue), BAILLY Sylvain 91390 MORSANG SUR
RGE (Cardiologue), BALADIER COULEAUD Valérie 91490
ILLY LA FORET (Cardiologue), BALIGADOU So Orianarain
2140 HESDIN (Cardiologue), BARBEAU Pascal 33200 BOR-
EAUX (Cardiologue), BARBIN Patrick 53200 CHÂTEAU
ONTIER (MG), BARRIERE Serge 64500 St Jean De Luziologue), BASLE Jérome 17137 NIEUL SUR MER (MG),
ATTLE Louis 37000 TOURS (Cardiologue), BATY Alain 53000
AVAL (MG), BAZILE Brigitte 31290 Villefranche De Lauragais
Cardiologue), BEARD Thierry 65000 TARBES (Cardiologue),
EIGBEDER Jean-Yves 64000 PAU (Cardiologue), BELLEFLEUR
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62400 BETHUNE (Cardiologue), FAURE Olivier 11000 CARCAS-Results of TWICE trial
Jean-Paul 10120 St André- Les-Vergers (Cardiologue), BEMU-
RAT Laurent 33610 CESTAS (Cardiologue), BENITAH Gérard
66100 PERPIGNAN (Cardiologue), BENITAH Elie 75010 PARIS
(Cardiologue), BENOIT Pierre-Olivier 35033 RENNES Cedex
9 (Cardiologue), BERDAGUE Philippe 34500 BEZIERS (Car-
diologue), BERDELLOU Thierry 93600 AULNAY S/ BOIS
(Cardiologue), BERNARD Jean-Pierre 14000 CAEN (Cardio-
logue), BERNARD Jacques 59000 LILLE (MG), BERNARDEAU
Claire 92150 SURESNES (Cardiologue), BERSAY Claude 75011
PARIS (Cardiologue), BERTHAUX Xavier 77220 TOURNAN EN
BRIE (Cardiologue), BERTRAND Jean-Henri 84100 ORANGE
(Cardiologue), BESSEKRI Abdelkader 67200 STRASBOURG
(Cardiologue), BINEAU Bertrand 53950 LOUVERNE (MG),
BINET Didier 50700 VALOGNES (Cardiologue), BLACHE Eric
13500 MARTIGUES (Cardiologue), BLANC Emile 20200 BAS-
TIA (Cardiologue), BLANCHARD Benoit 76600 LE HAVRE
(Cardiologue), BLISCAUX Pascale 57500 St AVOLD (Cardi-
ologue), BODUR Gokhan 68100 MULHOUSE (Cardiologue),
BOISSY Jean-Claude 83700 St RAPHAEL (Cardiologue), BOIT-
TIN Philippe 14400 BAYEUX (Cardiologue), BOLTE Francois
82000 MONTAUBAN (Cardiologue), BONNAFFE Benoît 44600
St NAZAIRE (Cardiologue), BORFIGA Jean-Franc¸ois 85180
CHATEAU d’OLONNE (Cardiologue), BOUCHAYA Toni 82000
MONTAUBAN (Cardiologue), BOUCHET Gérard 84200 CAR-
PENTRAS (Cardiologue), BOUCHUT Gilles 84800 L’Isle Sur La
Sorgue (Cardiologue), BOUCLY Jean-Marc 59330 HAUTMONT
(MG), BOUKHALIL Charles 72200 LA FLECHE (Cardiologue),
BOURAS Yahya 90000 BELFORT (Cardiologue), BOURDON
Catherine 13009 MARSEILLE (Cardiologue), BOURIAUD Michel
53950 LOUVERNE (MG), BOURNAZEL Vincent 49800 ANGERS
(Cardiologue), BOUSQUET Jean-Pierre 13009 MARSEILLE
(Cardiologue), BOUTAUD Philippe 86000 POITIERS (Car-
diologue), BOUTON BROCHET Sophie 92250 La Garenne
Colombes (Cardiologue), BOUVIER Eric 64300 ORTHEZ (Car-
diologue), BRAL Michel 93000 STAINS (Cardiologue), BRAULT
Franc¸ois 53200 CHÂTEAU GONTIER (MG), BREYSSE Hervé
13300 SALON De PROVENCE (Cardiologue), BROIN Patrick
74703 SALLANCHES (Cardiologue), BROSSE Frédéric 74200
THONON Les BAINS (Cardiologue), BROTTIER Luc 64200
BIARRITZ (Cardiologue), BRUA Jean-Luc 57400 SARREBOURG
(Cardiologue), BRUMELOT Franc¸ois 38000 GRENOBLE (Car-
diologue), BRUNEHAUT PETAUT Myriam 63100 CLERMONT-
FERRAND (Cardiologue), BRUNET Eric 59590 RAISMES (MG),
BUISSON Pierre 69001 LYON (Cardiologue), BURGGRAF
Christian 25200 MONTBELIARD (Cardiologue), BUSSIERE
Jean-Louis 74100 ANNEMASSE (Cardiologue), CADILHON
Jean-Claude 33120 ARCACHON (Cardiologue), CAILLAT
Muriel 92100 Boulogne Billancourt (Cardiologue), CAILLAUX
Bruno Xavier 21000 DIJON (Cardiologue), CARETTE Bernard
51100 REIMS (Cardiologue), CASTER Luc 31400 TOULOUSE
(Cardiologue), CAUDMONT Sébastien 59410 ANZIN (Cardio-
logue), CAUET Jacques 59100 ROUBAIX (Cardiologue), CAYOL
Claude 13160 Châteaurenard (Cardiologue), CAZIER Yves
76100 ROUEN (Cardiologue), CESARINI Joël 91150 ETAMPES
(Cardiologue), CHALTIEL Maurice-Gérard 38000 GRENOBLE
(Cardiologue), CHANTRELLE Alain 31400 TOULOUSE (Cardio-
logue), CHARRAD Raﬁk 91160 LONGJUMEAU (Cardiologue),
CHARRUAU Rémy 49800 TRELAZE (MG), CHEMIN Philippe
33200 BORDEAUX (Cardiologue), CHEVALIER Dominique
13010 MARSEILLE (Cardiologue), CHOPRA Soeb 78990 ELAN-
COURT (Cardiologue), CLARET-MONTE CATTINI Philippe
20220 L’ILE ROUSSE (Cardiologue), COHEN Alain 13002
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ARSEILLE (Cardiologue), COIGNARD Elisabeth 93120 LA
OURNEUVE (Cardiologue), COLIN Remy 83000 TOULON
Cardiologue), CONDOMINES Hervé 82000 MONTAUBAN (Car-
iologue), CONDOURET Pierre 75009 PARIS (Cardiologue),
ORBEL Claude 56110 GOURIN (Cardiologue), CORBIN André
2100 DINAN (Cardiologue), CORRAINI Bernard 03300 CUSSET
Cardiologue), COSSON Stephane 34500 BEZIERS (Cardio-
ogue), COSTE LEENHARDT Corinne 13100 Aix En Provence
Cardiologue), COUDRAY Nicolas 06800 CAGNES SUR MER
Cardiologue), COUFFIN Jean-Pierre 78250 MEULAN (Car-
iologue), COURDIER Guy 68100 MULHOUSE (Cardiologue),
OURTAULT Alain 31700 CORNEBARRIEU (Cardiologue), CRE-
PY Richard 34000 MONTPELLIER (Cardiologue), DAFFOS
icolas 93190 Sevran (Cardiologue), DAFFOS Catherine
3800 Epinay-Sur-Seine (Cardiologue), DAGRAN Olivier
3500 MARTIGUES (Cardiologue), DAHAN Simon Robert
7000 STRASBOURG (Cardiologue), DAHAN Jean-Maurice
6800 CAGNES SUR MER (Cardiologue), DAHAN Albert
1000 TOULOUSE (Cardiologue), DAILLET Etienne 84110
aison- la-Romaine (Cardiologue), DANEY Dominique 33390
LAYE (Cardiologue), DANY Franc¸ois 87000 LIMOGES (Car-
iologue), DASSE Alain 53200 CHÂTEAU GONTIER (MG),
ASSONVILLE Bernard 75014 PARIS (Cardiologue), DAVID
ean-Michel 53000 LAVAL (MG), DE ROQUEFEUIL Florence
5016 PARIS (Cardiologue), DEBOMY Alain 59000 LILLE
MG), DEHAUT Jean-Claude 02000 LAON (Cardiologue), DEL-
ECQUE Danièle 59200 TOURCOING (MG), DELHOMME Claire
6000 PERPIGNAN (Cardiologue), DELOY Pierre-Philippe
4400 APT (Cardiologue), DELPLACE MAURY Christelle 37000
OURS (Cardiologue), DELPONT Maurice 31240 ST JEAN
Cardiologue), DELUCHE Laurent 87100 LIMOGES (Cardio-
ogue), DEMASLES Christian 65100 LOURDES (Cardiologue),
EMATTEO Philippe 50700 VALOGNES (Cardiologue), DENIS
ucien 42400 St CHAMOND (Cardiologue), DEQUEKER Jean
Luc 64100 BAYONNE (Cardiologue), DEQUIDT Bernard
6100 ROUEN (Cardiologue), DESRUES Hervé 53000 LAVAL
MG), DESTOMBES Franc¸ois 59940 ESTAIRES (Cardiologue),
ESTRUBE Bernard 44240 LA CHAPELLE SUR ERDRE (MG),
EVOUASSOUX Charles 26400 CREST (Cardiologue), DIEBOLD
ervé 75116 PARIS (Cardiologue), DISY Jean-Franc¸ois 44600
t NAZAIRE (Cardiologue), DOMEREGO Jean-Jacques 06000
ICE (Cardiologue), DUC Philippe 94120 Fontenay Sous Bois
Cardiologue), DUCHENE Pierre 49460 FENEU (MG), DUCOS
écile 33240 St André De Cubzac (Cardiologue), DUCOUDRE
ichel 64200 BIARRITZ (Cardiologue), DUMORTIER Daniel
9800 LILLE (Cardiologue), DUPONT Thierry 59530 Le Ques-
oy (Cardiologue), DURAFOURG Luc 11000 CARCASSONNE
Cardiologue), DURANDET Philippe 17000 LA ROCHELLE
Cardiologue), DUROY Christian 53000 LAVAL (MG), ELA-
EE Abdoul 06150 Cannes La Bocca (Cardiologue), ELIAKIM
gnès 77270 VILLEPARISIS (Cardiologue), EOCHE Roger 44300
ANTES (MG), ESCARGUEL Didier 11000 CARCASSONNE (Car-
iologue), ETLINGER Philippe 75009 PARIS (Cardiologue),
YMARD Claude 47000 AGEN Cedex (Cardiologue), FALK
laudine 92230 GENNEVILLIERS (Cardiologue), FALQUIER
ean-Franc¸ois 24100 BERGERAC (Cardiologue), FARAH Bruno
1076 TOULOUSE Cedex 3 (Cardiologue), FARGES Jean-LouisONNE (Cardiologue), FAVREAU Bernard 49300 CHOLET (MG),
EDOROWSKY Alain 78800 HOUILLES (Cardiologue), FELD-
ANN Israel 67500 HAGUENEAU (Cardiologue), FERRER Jean-
laude 13150 TARASCON (Cardiologue), FERRINI Marc 69006
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YON (Cardiologue), FISCHBEIN Laurent 77500 CHELLES (Car-
iologue), LINOIS Pascale 13340 ROGNAC (Cardiologue),
ONTANEY Franck 42400 St CHAMOND (Cardiologue), FOU-
ERT Olivier 53200 CHÂTEAU GONTIER (MG), FOURNIER
ean-Bernard 30000 NIMES (Cardiologue), FOURNIER Jean-
ranc¸ois 76190 YVETOT (Cardiologue), FOURNIER Eric
5000 GAP (Cardiologue), FRADIN Dominique 49300 CHO-
ET (Cardiologue), FRAYSSE Jean-Bernard 19100 Brive
a Gaillarde (Cardiologue), FRITZ André 67600 SELESTAT
Cardiologue), FRUCHART Bruno 62400 BETHUNE (Cardio-
ogue), GAILLARDE Bernard 66000 PERPIGNAN (Cardiologue),
ALEY Arsène 02400 CHÂTEAU THIERRY (Cardiologue),
ANDON Thierry 51100 REIMS (Cardiologue), GARANDEAU
arie 71600 Paray-Le-Monial (Cardiologue), GARCIA Philippe
3300 DRAGUIGNAN (Cardiologue), GARTENLAUB Olivier
4700 MAISONS ALFORT (Cardiologue), GASTON Franc¸ois
illes 31320 Castanet Tolosan (Cardiologue), GAUSSERAND
ichel 81000 ALBI (Cardiologue), GAUTHIER Jean 13200
RLES (Cardiologue), GENOT Marcel 54000 NANCY (Cardio-
ogue), GERBE Alain 14400 BAYEUX (Cardiologue), GERNIGON
atrick 44470 CARQUEFOU (MG), GILLET Thierry 83000
OULON (Cardiologue), GIRAUD Patrick 84300 CAVAILLON
Cardiologue), GOBERT JACKEL Véronique 33150 CENON
Cardiologue), GOISSEN Patrick 40800 AIRE SUR ADOUR (Car-
iologue), GOMBAUD Daniel 49000 ANGERS (MG), GORISSE
lain 59160 LOMME (MG), GOURDON Olivier 66000 PERPIG-
AN (Cardiologue), GOURGON SARAZIN Dominique 78600
AISONS LAFFITTE (Cardiologue), GRANGER Gérard 36100
SSOUDUN (Cardiologue), GRAS Emmanuel 62110 HENIN
EAUMONT (Cardiologue), GRASSART Emmanuel 59138
ACHANT (MG), GRENIER Olivier Jean Yves 75008 PARIS
Cardiologue), GRIVET Bruno 69003 LYON (Cardiologue),
ROS André 46000 CAHORS (Cardiologue), GUDIN DE VAL-
ERIN Michel 75116 PARIS (Cardiologue), GUEDJ Pierre
5009 PARIS (Cardiologue), GUEDJ Dominique 75116 PARIS
Cardiologue), GUERANGER Pierre 12200 Villefranche De
ouergue (Cardiologue), GUEZ Philippe 84200 CARPENTRAS
Cardiologue), GUILLEM Jean-Pierre 17000 LA ROCHELLE
Cardiologue), GUILLOT Philippe 34200 SETE (Cardiologue),
UILLOUX Jean-Paul 31410 LONGAGES (Cardiologue), GUIR-
HOWSKI Alain 06300 NICE (Cardiologue), GURDA Marek
8500 SARTROUVILLE (Cardiologue), GUTEL Bertrand 95330
OMONT (Cardiologue), HADDAD Jean-Claude PARIS (Cardio-
ogue), HALFON Jean-Pierre 31270 CUGNAUX (Cardiologue),
ALLALI Patrick 38000 GRENOBLE (Cardiologue), HALPHEN
VADIA Christine 78100 St Germain En Laye (Cardiologue),
AMEL Emmanuel 37000 TOURS (Cardiologue), HAMWI
bdel Hamid 75019 PARIS (Cardiologue), HANRION Pascal
9110 MONTREVAULT (MG), HASSAN Gilbert 13007 MAR-
EILLE (Cardiologue), HASSON Bernard 13009 MARSEILLE
Cardiologue), HELMS Eric 69800 St PRIEST (Cardiologue),
ELOU Nabil 60300 SENLIS (Cardiologue), HERENT Marc
9410 ANZIN (MG), HETHUIN Jean-Michel 59400 CAMBRAI
Cardiologue), HEULS Sébastien 59650 Villeneuve D’Ascq
Cardiologue), HIJAZI Bernard 30900 NIMES (Cardiologue),
ITA André 84400 APT (Cardiologue), HODROGE Henri 27200
ERNON (Cardiologue), HOFFMAN Olivier 75018 PARIS (Car-
iologue), HOROVITZ Daniel 91600 Savigny Sur Orge (Car-
iologue), HOURANY Antoine 14100 LISIEUX (Cardiologue),
UG Christian 66000 PERPIGNAN (Cardiologue), HUYGHE
ominique 59300 VALENCIENNES (MG), IGIGABEL Philippe
9125 TIERCE (MG), ISOARD Jacques 06140 VENCE (Cardio-
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ogue), JAUFFRET Bernard 13007 MARSEILLE (Cardiologue),
EAN Stéphane 17200 ROYAN (Cardiologue), JEANVOINE
enry 49000 ANGERS (Cardiologue), JELEN Pascal 17000
A ROCHELLE (MG), JEREMIAZ Richard 75013 PARIS (Car-
iologue), JOSEPH Jean-Paul 83150 BANDOL (Cardiologue),
UBERT Rémy 37300 JOUE LES TOURS (Cardiologue), JULIEN
runo 40100 DAX (Cardiologue), JULLIEN Jean-Louis 75017
ARIS (Cardiologue), KADOUCH James 75017 PARIS (Car-
iologue), KALESKI Patricia 06600 ANTIBES (Cardiologue),
AYL BOILEVIN Dominique 57038 METZ Cedex 01 (Cardio-
ogue), KEDRA Antoni Wojcieck 75010 PARIS (Cardiologue),
ERRAD Louisa 78450 VILLEPREUX (Cardiologue), KETELERS
égis 59280 ARMENTIERES (Cardiologue), KHAN Moin 02000
AON (Cardiologue), KHAZNADAR Guy 75011 PARIS (Car-
iologue), KHOURY Franc¸ois 11300 LIMOUX (Cardiologue),
HOURY Kamal 06190 Roquebrune Cap Martin (Cardiologue),
OHAN Patrick 54000 NANCY (Cardiologue), KORCZYNSKI
obert 26000 VALENCE (Cardiologue), KOZLOWSKI Fran-
is 59200 TOURCOING (Cardiologue), KREBS Renaud 13200
RLES (Cardiologue), KRONEK Didier 59590 RAISMES (MG),
ABEDAN Frédéric 92500 RUEIL MALMAISON (Cardiologue),
ABIB Marie 78340 Les Clayes Sous Bois (Cardiologue),
AGIEWKA Christian 93300 AUBERVILLIERS (Cardiologue),
AINE Eric 80094 AMIENS Cedex 3 (Cardiologue), LAISNE
aoul 53000 LAVAL (MG), LAMBERT Michel 49100 ANGERS
MG), LANDEL Rémi 22015 St BRIEUC Cedex 1 (Cardi-
logue), LANG Philippe 68200 MULHOUSE (Cardiologue),
APEYRE Guy 81000 ALBI (Cardiologue), LARLET Jean-
arie 56600 LANESTER (Cardiologue), LAUGA Dominique
4300 ORTHEZ (Cardiologue), LAURENT Jean-Claude 18100
IERZON (Cardiologue), LAURIER Bernard 78400 CHATOU
Cardiologue), LAURY Patrice 12000 RODEZ (Cardiologue),
AVABRE Guy 83140 Six Fours Les Plages (Cardiologue),
AVIGNE Guy 37000 TOURS (Cardiologue), LE MENAGER
ervé 44000 NANTES (Cardiologue), LE PODER Jean-Franc¸ois
6100 LORIENT (Cardiologue), LEANDRI Michel 63000 CLER-
ONT FERRAND (Cardiologue), LECERF Jean-Michel 59000
ILLE (Cardiologue), LEHUJEUR Catherine 34110 FRON-
IGNAN (Cardiologue), LEIBER Christian 68200 MULHOUSE
Cardiologue), LEJAY Dominique 59690 VIEUX CONDE (MG),
EMAIRE Pierre 62806 LIEVIN Cedex (Cardiologue), LENNE
hilippe 06200 NICE (Cardiologue), LEPENNEC Pascale 49300
HOLET (MG), LEROY Pierre 49000 ANGERS (MG), LEROY
ves 49000 ANGERS (MG), LERUSTE Sébastien 59310 LAN-
AS (MG), LEVEAU Xavier 49000 ANGERS (MG), LEVY Alain
5009 PARIS (Cardiologue), LEVY Richard 06700 St Laurent
u Var (Cardiologue), LEY Nicolas 65000 TARBES (Cardio-
ogue), LIM Du Quang 92400 COURBEVOIE (Cardiologue),
OBEL Christian 62000 ARRAS (Cardiologue), LONGERE
hilippe 83300 DRAGUIGNAN (Cardiologue), LONGUEVILLE
régoire 58000 NEVERS (Cardiologue), LOPEZ Jean-Philippe
9330 HAUTMONT (MG), LORENTZ Christian 90000 BELFORT
Cardiologue), LOUCHART Jean-Christophe 62400 BETHUNE
Cardiologue), MACAREZ Marcel 59287 GUESNAIN (Cardi-
logue), MAES Damien 59200 TOURCOING (Cardiologue),
AFFERT Etienne 17000 LA ROCHELLE (Cardiologue), MAG-
US Patricia 68800 THANN (Cardiologue), MAICHE Elisabeth
4240 LA CHAPELLE SUR ERDRE (MG), MAIGNIEN Jean-
ierre 25000 BESANCON (Cardiologue), MAILLY Denys 31370
ERAT (Cardiologue), MAKKI Hamid 21400 Chatillon sur
eine (Cardiologue), MALDONADO Philippe 38130 ECHI-
OLLES (Cardiologue), MANCHET Guy 25000 BESANCON
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(Cardiologue), MANLAY William 33000 BORDEAUX (Car-
diologue), MANNESSIER Bruno 59243 QUAROUBLE (MG),
MARACHLI Mathieu 18200 Saint Amand Montrond (Cardi-
ologue), MARCO Frédéric 31400 TOULOUSE (Cardiologue),
MARDEMOOTOO Madhaven 30100 ALES (Cardiologue), MAREK
Alain 80094 AMIENS Cedex 03 (Cardiologue), MARIN Denis
49125 BRIOLLAY (MG), MARLIER Mathieu 59130 LAMBER-
SART (MG), MARQUET Michel 05000 GAP (Cardiologue),
MARTIN Michel 71600 PARAY LE MONIAL (Cardiologue), MAR-
TIN Pierre-Etienne 13005 MARSEILLE (Cardiologue), MARTIN
Olivier 06000 NICE (Cardiologue), MASSABIE Raymonde 78310
MAUREPAS (Cardiologue), MASSELOT Michel 62700 Bruay
La Buissiere (Cardiologue), MASSON Jean-Jacques 37700 St
Pierre Des Corps (Cardiologue), MASSON Christophe 34080
MONTPELLIER (Cardiologue), MATHIEU Jean-Philippe 74000
ANNECY (Cardiologue), MAUDIERE Arnaud 37000 TOURS (Car-
diologue), MAURICE William 49000 ANGERS (MG), MAURIN
Philippe 48000 MENDE (Cardiologue), MAZE Jean Marie 49800
TRELAZE (MG), MEBARKIA Mansour 14400 BAYEUX (Cardio-
logue), MERCIER Gilles 59970 FRESNES SUR ESCAUT (MG),
MEROUE Samuel 94110 ARCUEIL (Cardiologue), MESLI
Zoubir 34070 MONTPELLIER (Cardiologue), MEYNIER Jean
87000 LIMOGES (Cardiologue), MICHEL Jean-Marie 67200
STRASBOURG (Cardiologue), MIKLER Francis 38600 FONTAINE
(Cardiologue), MOJON Franc¸oise 95330 DOMONT (Cardio-
logue), MOLINIER Franc¸oise 31081 TOULOUSE (Cardiologue),
MONIN Richard 26100 Romans Sur Isere (Cardiologue),
MONKA Louis 06000 NICE (Cardiologue), MONNET DE LOR-
BEAU Béatrice 41600 Lamotte Beuvron (Cardiologue),
MONNIER Gilles 69250 Neuville Sur Saône (Cardiologue),
MOREL Charles 42300 ROANNE (Cardiologue), MOTHES
Philippe 64000 PAU (Cardiologue), MOUHAT Thierry 25400
AUDINCOURT (Cardiologue), MULLER Jean-Joseph 67000
STRASBOURG (Cardiologue), NAGENRANFT Bernard 95100
ARGENTEUIL (Cardiologue), NAVA Guy 26700 PIERRELATTE
(Cardiologue), NECILI Yasmina 17000 LA ROCHELLE (Car-
diologue), NEGRIER Michel 81400 CARMAUX (Cardiologue),
OLIER Pierre 57150 Creutzwald (Cardiologue), OLIVIERI
Bernard 06160 JUAN LES PINS (Cardiologue), OUAZANA
Léon 75015 PARIS (Cardiologue), PALOMBA Alain 49000
ANGERS (MG), PAPOLA Philippe 57360 Amneville Les
Thermes (Cardiologue), PAREATHUMBY Kumaressen 66500
PRADES (Cardiologue), PARRENS Eric 33200 BORDEAUX
(Cardiologue), PASCARIELLO Jean-Claude 13008 MARSEILLE
(Cardiologue), PASCO Alain 67800 Bischheim (Cardiologue),
PECKRE Bernard 59910 BONDUES (MG), PEDEBOSCQ Georges
40000 MONT DE MARSAN (Cardiologue), PEDELHEZ Karine
59300 VALENCIENNES (Cardiologue), PELLISSIER Eric 06000
NICE (Cardiologue), PETIT Alain 62120 AIRE SUR LA LYS
(Cardiologue), PETIT Luc 38000 GRENOBLE (Cardiologue),
PEYRETOU Robert 33150 CENON (Cardiologue), PEYRONY
Alain 79200 PARTHENAY (Cardiologue), PICARD Jean-Claude
07200 AUBENAS (Cardiologue), PICHON Eric 70000 VESOUL
(Cardiologue), PIERI Bertrand 84120 PERTUIS (Cardiologue),
PIERRON Fabrice 13380 Plan de Cuques (Cardiologue),
PINZANI Alain 34200 SETE (Cardiologue), PLESKOF Alain
77500 CHELLES (Cardiologue), POLARD Franc¸ois 59000
LILLE (MG), POUCHELON Elisabeth 31300 TOULOUSE (Car-
diologue), POUJOIS Jean-Noël 08000 Charleville Mezieres
(Cardiologue), PRADIES Félix 66500 PRADES (Cardiologue),
PREISS Jean-Philippe 67000 STRASBOURG (Cardiologue),
PRESTAT Marie-Paule 83400 HYERES (Cardiologue), PROST
P
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hristophe 38200 VIENNE (Cardiologue), PROULT Marc 83110
ANARY SUR MER (Cardiologue), PRUNIER Laurent 93100
ONTREUIL (Cardiologue), PUEL Vincent 33000 BORDEAUX
Cardiologue), QUANDALLE Philippe 59100 ROUBAIX (Cardi-
logue), RAPHAEL Mikhael 13400 AUBAGNE (Cardiologue),
AYMOND Patrice 92600 Asnieres Sur Seine (Cardiologue),
EGEARD Eric 63130 ROYAT (Cardiologue), REMAUD Philippe
9000 ANGERS (MG), RENAULT LAMAZE Guy 91540 MEN-
ECY (Cardiologue), RENOU Dominique 49300 CHOLET
MG), REYGROBELLET Pierre 34090 MONTPELLIER (Cardio-
ogue), REYNERT Roland 67100 STRASBOURG (Cardiologue),
ICHARD Philippe 09000 FOIX (Cardiologue), RICHARD GRA-
IET Joëlle 40000 MONT De MARSAN (Cardiologue), RIJAVEC
oja 25290 ORNANS (Cardiologue), ROBERT Patrick 53000
AVAL (MG), ROBILLON Jean-Francois 98000 MONACO (Car-
iologue), ROBIN Sébastien 17000 LA ROCHELLE (MG),
OBINE Jean-Philippe 69400 Villefranche Sur Saone (Cardio-
ogue), RODIER Bernard 34000 MONTPELLIER (Cardiologue),
OLLAND Olivier 31080 TOULOUSE (Cardiologue), ROMANO
ean-Paul 13003 MARSEILLE (Cardiologue), ROOS Clément
7200 STRASBOURG (Cardiologue), ROSSET Michel 06200
ICE (Cardiologue), ROSSIGNOL Bruno 38028 GRENOBLE
edex 1 (Cardiologue), ROUESNEL Philippe 41100 VEN-
OME (Cardiologue), ROUGE Jean-Franc¸ois 34120 PEZENAS
Cardiologue), ROUMANEIX Daniel 59220 DENAIN (MG),
OURE Brigitte 74400 Chamonix Mont Blanc (Cardiologue),
OVANI Xavier 77340 Pontault Combault (Cardiologue),
UAULT Pierre-Hervé 75016 PARIS (Cardiologue), SALAMA
ngèle 28100 DREUX (Cardiologue), SALEH Bahige 69009
YON (Cardiologue), SAMAMA Philippe 84200 CARPEN-
RAS (Cardiologue), SANANES Roland 77220 TOURNAN EN
RIE (Cardiologue), SANDALIAN Alain 13012 MARSEILLE
Cardiologue), SANDER Marc 78100 St Germain En Laye
Cardiologue), SARDA Robert 11000 CARCASSONNE (Cardio-
ogue), SAVELLI Jacques 83700 St RAPHAEL (Cardiologue),
CHENOWITZ Alain 06000 NICE (Cardiologue), SCHOTT
ernard 67500 HAGUENAU (Cardiologue), SEBAOUN Edouard
3380 PLAN DE CUQUES (Cardiologue), SEBAOUN Alain
5015 PARIS (Cardiologue), SEKONIAN Richard 13012 MAR-
EILLE (Cardiologue), SENELLART Franc¸ois 38000 GRENOBLE
Cardiologue), SIBONY Yves 67600 SELESTAT (Cardiologue),
IGOGNEAU Jean-Marc 57400 SARREBOURG (Cardiologue),
IMONIN Annie 74100 ANNEMASSE (Cardiologue), SMADJA
anièle 59650 Villeneuve D’Ascq (Cardiologue), SOLANET
enaud 59100 ROUBAIX (MG), SOUKARIE Laurent 31650 St
rens de Gameville (Cardiologue), SPECHT Lionel 59130
AMBERSART (MG), SPILLEMAECKER Benoît 85180 Château
’Olonne (Cardiologue), SPITERI Jean-Louis 75015 PARIS
Cardiologue), STIOUI Bernard 95140 GARGES (Cardiologue),
USINI Georges 20200 BASTIA (Cardiologue), TABET Stéphane
5880 ENGHIEN LES BAINS (Cardiologue), TARABBIA Philippe
4100 BAYONNE (Cardiologue), TARDIEU André 82000 MON-
AUBAN (Cardiologue), TARDY Claude 66000 PERPIGNAN
Cardiologue), TESSIER Pascal 83700 St RAPHAEL (Cardi-
logue), THILLEUL Philippe 10000 TROYES (Cardiologue),
HOIN Fabrice 13006 MARSEILLE (Cardiologue), THOMAS
ICHARD Franck 18000 BOURGES (Cardiologue), TILMANT
ierre-Yves 59400 CAMBRAI (Cardiologue), TIMSIT Gilles
5019 PARIS (Cardiologue), TISON Eric 59800 LILLE (Car-
iologue), TISSOT Marc 25300 PONTARLIER (Cardiologue),
OBAN Pascal 37100 TOURS (Cardiologue), TONDUT Jacques
9000 ANGERS (MG), TONDUT Jérome 17000 LA ROCHELLE
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MG), TRAISNEL Gilles 59000 LILLE (Cardiologue), TRICOIRE
acques 31000 TOULOUSE (Cardiologue), TRICOT Cather-
ne 17000 LA ROCHELLE (Cardiologue), TRUONG MINH KY
ernard 64000 PAU (Cardiologue), TUBIANA Marie 06110
E CANNET (Cardiologue), TURMEL Jacques 79000 NIORT
Cardiologue), URBINA Jean-Charles 59224 THIANT (MG),
ACOSSIN Christian 51200 EPERNAY (Cardiologue), VAIS-
IC Claude 78150 LE CHESNAY (Cardiologue), VALIN Marc
3001 LAVAL (MG), VASSEUR Philippe 62100 CALAIS (Cardio-
ogue), VERSCHUEREN Philippe 77130 Montereau Fault Yonne
Cardiologue), VERVIN Pierrick 78600 MAISONS LAFFITTE
Cardiologue), VIAL Hubert 13008 MARSEILLE (Cardiologue),
IEL Christophe 17000 LA ROCHELLE (MG), VIGNE Jean-
arc 59600 MAUBEUGE (Cardiologue), VIOLET Thibaud 74000
NNECY (Cardiologue), VIRCOULON Bernard 33220 Ste Foy
a Grande (Cardiologue), VITOUX Jean-Franc¸ois 92000 NAN-
ERRE (Cardiologue), VITTECOQ Bruno 91240 St Michel Sur
rge (Cardiologue), VOGEL Jacques 59170 CROIX (MG),
OGEL Marc 59390 TOUFFLERS (MG), VOGLIMACCI Michel
5000 TARBES (Cardiologue), WALCH Jean-Michel 93600
ulnay-Sous-Bois (Cardiologue), WATTEAU Damien 44000
Cardiologue), WAZANA Michel 67000 STRASBOURG (Cardio-
ogue), WEILL Didier 88100 St DIE (Cardiologue), WIND Pierre
7200 MARMANDE (Cardiologue), WONG Olivier 84130 LE
ONTET (Cardiologue), WORINGER Philippe 34800 Clermont
’Hérault (Cardiologue), ZARTARIAN Serge 06140 VENCE (Car-
iologue), ZEITOUNI Roland 94250 GENTILLY (Cardiologue),
ITOUN Jacques 83200 TOULON (Cardiologue), ZYLBERBERG
ichel 12200 Villefranche De Rouergue (Cardiologue).
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